Nile Therapeutics, Inc. Share Price Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
13/05 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
13/05 | Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M | MT |
Sales 2024 * | 22.1M 1.84B | Sales 2025 * | 168M 14B | Capitalization | 164M 13.67B |
---|---|---|---|---|---|
Net income 2024 * | -38M -3.17B | Net income 2025 * | 53M 4.42B | EV / Sales 2024 * | 7.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.98 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
3.97
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.37% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20/13/20 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20/13/20 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21/23/21 |
Earl Collier
BRD | Director/Board Member | 76 | 20/13/20 |
George Dunbar
BRD | Director/Board Member | 77 | 20/13/20 |
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.46% | 21.25B | |
-5.85% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |